Fabiola Reis Oliveira

Dr. Fabiola Reis Oliveira


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TRTamara S. Rodrigues
Tamara S. Rodrigues
KSKeyla Sá
Keyla Sá
AIAdriene Y. Ishimoto
Adriene Y. Ishimoto
ABAmanda Becerra
Amanda Becerra
SOSamuel Oliveira
Samuel Oliveira
DZDario S. Zamboni
Dario S. Zamboni
Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1β, and IL-18. Although participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease are unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and is active in COVID-19 patients. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of postmortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that inflammasomes participate in the pathophysiology of the disease, indicating that these platforms might be a marker of disease severity and a potential therapeutic target for COVID-19.

1 July 2022 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
FOFabiola Reis Oliveira
Fabiola Reis Oliveira
AMAna Carolina Fragoso Motta
Ana Carolina Fragoso Motta
CMCarolina Maria Módulo
Carolina Maria Módulo
DGDenny Marcos Garcia
Denny Marcos Garcia
JCJohn A. Chiorini
John A. Chiorini
Eduardo RochaEduardo Rocha
Eduardo Rocha
Background: Sjögren Syndrome (SS) is a systemic autoimmune disease with a wide spectrum of manifestations that can lead to misdiagnosis. This study describes and compares demographic, clinical, serological, and histopathological data from subjects with SS and non-Sjögren Syndrome (NSS). It also details specific features within the primary SS (pSS) and secondary SS (sSS) groups identifying sub-groups.Methods: The sample included individuals referred to an academic medical center in Brazil for investigation of SS from 2012 to 2020. Patients were retrospectively classified as primary SS (pSS), secondary SS (sSS), or NSS, based on the American-European Consensus Group criteria (AECG-2002), after multi-professional clinical and laboratory evaluation.Results: A total of 676 individuals were screened and 510 (75.4%) completed the assessments; 198 patients were classified as pSS, 149 as sSS, and 163 as NSS. Symptoms and glandular dysfunction tests were similar in the groups. Concerning pSS, extraglandular manifestations were present in 59% of patients; the elderly had more dry symptoms and peripheral neurological disorders; and 2.5% developed non-Hodgkin lymphoma. In sSS, each overlap promoted distinct clinical and laboratory variants. Several alternative diagnoses were identified as a cause of sicca complex in NSS group.Conclusions: The diagnosis of SS remains a challenge behind dryness. Up to 31% of the suspected cases had other conditions associated to the symptoms. Histopathological analysis of LSG and SSa determined the diagnostic. Aging in pSS and overlap disease in sSS were responsible for distinct phenotypes and characteristic sub-groups in SS.

11 February 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
FOFabiola Reis Oliveira
Fabiola Reis Oliveira
SASimone Appenzeller
Simone Appenzeller
SPSandra Gofinet Pasoto
Sandra Gofinet Pasoto
MFMarilena Leal Mesquita Silvestre Fernandes
Marilena Leal Mesquita Silvestre Fernandes
MLMaria Lucia Lemos Lopes
Maria Lucia Lemos Lopes
VTVirginia Fernandes Moça Trevisani
Virginia Fernandes Moça Trevisani
Background: Neurological and psychiatric manifestations occur in patients with primary Sjogren’s disease (SjD) with a wide-ranging clinical presentation, affecting quality of life, social participation, and prognosis. Despite this, neither central nor peripheral neurological symptoms are systematically evaluated in the context of autoimmunity or identified as manifestations of SjD. The EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) covers only part of them in the neurological domain. Methods: We performed a systematic review of the diagnosis and prevalence of central, peripheral, and autonomic nervous system manifestations in primary SjD, following the recommendations proposed by the Cochrane Collaboration Handbook. Observational studies were included when their main issue was the diagnosis and the prevalence of the manifestations individually. We employed a generalized linear mixed model (GLMM) method with a random-effects model, and the results were computed using logit transformation, implemented through the ‘meta’ and ‘metafor’ packages in the R software (version 3.6.1). To present these recommendations, agreement among experts was investigated using the Delphi method in in-person meetings. Results: We propose ten recommendations regarding the investigation and management of neurological involvement in SjD that had 100% agreement among participants. Conclusion: These recommendations add to the literature on the clinical care of patients with SjD.

3 April 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JGJaciara M. Gomes-Silva
Jaciara M. Gomes-Silva
CTCarolina Torres
Carolina Torres
LTLucas R. Teixeira
Lucas R. Teixeira
MSMaria da Conceição P. Saraiva
Maria da Conceição P. Saraiva
FOFabiola Reis Oliveira
Fabiola Reis Oliveira
AMAna Carolina Fragoso Motta
Ana Carolina Fragoso Motta

8 January 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
GCGraziela Cavalcanti
Graziela Cavalcanti
FOFabiola Reis Oliveira
Fabiola Reis Oliveira
RFRafael Ferraz-Bannitz
Rafael Ferraz-Bannitz
NPNatália Aparecida De Paula
Natália Aparecida De Paula
AMAna Carolina Fragoso Motta
Ana Carolina Fragoso Motta
LFLUIZ CARLOS CONTI DE FREITAS
LUIZ CARLOS CONTI DE FREITAS
Background: Endoplasmic reticulum stress (ERS) and the unfolded protein response (UPR) are adaptive mechanisms for conditions of high protein demand, marked by an accumulation of misfolded proteins in the endoplasmic reticulum (ER). Rheumatic autoimmune diseases (RAD) are known to be associated with chronic inflammation and an ERS state. However, the activation of UPR signaling pathways is not completely understood in Sjögren’s disease (SD). This study evaluated the expression of ERS-related genes in glandular tissue of patients with primary SD (pSD), associated SD (aSD) with other autoimmune diseases, and non-Sjögren sicca syndrome (NSS). Methods: In a cross-sectional study, minor salivary gland biopsies were obtained from 44 patients with suspected SD and 13 healthy controls (HC). Patients were classified as pSD, aSD, or NSS based on clinical, serological, and histological assessment. Histopathological analysis and mRNA expression analysis of genes associated with ERS and UPR (PERK, XBP1, ATF-6, ATF-4, CANX, CALR, CHOP, and BIP) were performed on the samples. Differences between groups (pSD, aSD, NSS, and HC) were assessed. The influence of chloroquine (CQ) on the ER was also investigated. Results: Twenty-eight SD patients showed increased expression of PERK ( p = 0.0117) and XBP1 ( p = 0.0346), and reduced expression of ATF-6 ( p = 0.0003) and CHOP ( p = 0.0003), compared to the HC group. Increased expression of BIP ( p < 0.0001), PERK ( p = 0.0003), CALR ( p < 0.0001), and CANX ( p = 0.0111) was also observed in the SD group compared to the NSS group ( n = 16). Patients receiving CQ ( n = 16) showed a significant increase in ATF-6 ( p = 0.0317) compared to patients not taking the medication ( n = 29). Conclusions: Altogether, the results suggest a greater activation of the ERS and UPR genes in patients with SD, especially in the pSD group. Antimalarial drugs, like CQ, used to treat RAD, may affect the ER function in exocrine glands.

9 July 2025 in Vision
Verified
Journal Article
Open access
PDF file
MMMateus Maia Marzola
Mateus Maia Marzola
DGDiego Rocha Gutierrez
Diego Rocha Gutierrez
BCBeatriz Carneiro Cintra
Beatriz Carneiro Cintra
AMAdriana de Andrade Batista Murashima
Adriana de Andrade Batista Murashima
LDLuciana Dalmolin
Luciana Dalmolin
Eduardo RochaEduardo Rocha
Eduardo Rocha
Dry eye disease (DED) is a hallmark of primary Sjögren’s disease (SjD) and often resists conventional treatments like lubricant eye drops. Insulin nanoemulsions offer a potential solution by improving drug penetration and retention on the ocular surface. In animal models, insulin has shown benefits in promoting tear secretion and corneal healing. This study evaluated the safety and efficacy of insulin nanoemulsion eye drops (20 IU/mL, three times daily for 30 days) in patients with SjD. Thirty-two patients were randomized in a double-masked design to receive either insulin or placebo drops. Symptoms (assessed by OSDI questionnaire) and objective measures (tear film breakup time, corneal and conjunctival staining, and Schirmer Test) were recorded at baseline, after 4 weeks of treatment, and at a 4-week follow-up. Twenty-three participants completed the study. Both groups showed significant improvement in symptoms and objective signs after treatment (p < 0.05), but no significant differences were found between the insulin and placebo groups. No clinically relevant adverse effects were reported. Insulin nanoemulsion eye drops are safe for SjD patients, but their therapeutic advantage remains unclear. Further studies with larger samples, extended follow-up, and dose adjustments are needed to better understand their potential.